Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of “Buy” by Analysts

Dyne Therapeutics, Inc. (NASDAQ:DYN) has earned a consensus recommendation of “Buy” from the fifteen research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, twelve have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $47.46.

DYN has been the subject of a number of recent research reports. Scotiabank assumed coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price target for the company. Chardan Capital reissued a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 17th. Piper Sandler reduced their price objective on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Finally, HC Wainwright restated a “buy” rating and set a $46.00 price target on shares of Dyne Therapeutics in a report on Monday, March 17th.

Dyne Therapeutics Stock Performance

DYN stock opened at $7.85 on Wednesday. Dyne Therapeutics has a fifty-two week low of $6.36 and a fifty-two week high of $47.45. The company has a market capitalization of $888.00 million, a price-to-earnings ratio of -2.21 and a beta of 1.21. The business’s 50 day moving average price is $11.52 and its two-hundred day moving average price is $20.97.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.04. Sell-side analysts forecast that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Insider Transactions at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares of the company’s stock, valued at $2,777,263.65. The trade was a 1.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 6,237 shares of company stock worth $77,760 in the last three months. Corporate insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DYN. Janus Henderson Group PLC increased its stake in shares of Dyne Therapeutics by 8.3% in the fourth quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company’s stock worth $173,808,000 after purchasing an additional 566,146 shares in the last quarter. State Street Corp increased its stake in Dyne Therapeutics by 13.8% in the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company’s stock worth $130,816,000 after buying an additional 440,890 shares in the last quarter. Geode Capital Management LLC raised its holdings in Dyne Therapeutics by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 1,887,329 shares of the company’s stock valued at $44,476,000 after acquiring an additional 27,916 shares during the period. Jefferies Financial Group Inc. purchased a new position in shares of Dyne Therapeutics in the fourth quarter valued at about $42,408,000. Finally, Orbimed Advisors LLC lifted its position in shares of Dyne Therapeutics by 73.2% in the fourth quarter. Orbimed Advisors LLC now owns 1,227,080 shares of the company’s stock valued at $28,910,000 after acquiring an additional 518,680 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.